Related Experiment Video
Updated: May 17, 2026

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice
Published on: June 7, 2024
Pharmaceutical standardization of Jala Shukti Bhasma and Mukta Shukti Bhasma
Kirti Kumar G Parmar1, Galib, B J Patgiri
1Ayurvedic Practitioner, Department of Rasa Shastra and Bhaishajya Kalpana Including Drug Research, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India.
Abstract:
Shukti is an important component of Sudha Varga, which is considered as the latest class in the field of Rasa Shastra. Two types of Shukti have been mentioned in Rasa Shastra texts i.e. Jala Shukti and Mukta Shukti according to the availability. In present study, an attempt has been made to develop a standard manufacturing procedure (SMP) of Jala Shukti Bhasma and Mukta Shukti Bhasma. Five batches of Jala Shukti Bhasma and Mukta Shukti Bhasma were prepared and standardization was attempted by maintaining batch manufacturing records of individual batches. During pharmaceutical procedures like Shodhana, Bhavana, Marana, etc. due care of temperature, its duration, percentage of weight gain or loss and the cost factor of the end product, etc. were considered. The average weight loss observed was 12.08 g i.e. 2.42% and 14.62 g i.e. 2.92% during Jala Shukti and Mukta Shukiti Shodhana respectively. Average weight loss found was 38.94 g i.e. 7.79% in Jala Shukti Bhasma while in Mukta Shukti Bhasma, it was 35.24 g i.e. 7.05%. At the end of the pharmaceutical procedure, it was found that Mukta Shukti Bhasma is 2.8 times costlier than Jala Shukti Bhasma.
Related Concept Videos
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmaceutical Equivalents
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
